FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE.
Blood. 2015 Jun 11;125(24):3674-5. doi: 10.1182/blood-2015-04-641704.
In this issue of Blood, Chalandon et al report the results of a prospective randomized study comparing standard vs less-intensive chemotherapy, both combined with imatinib, for patients with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). They show that the less-intensive therapy reduces early mortality without impairing efficacy, resulting in a significantly higher hematologic complete remission (CR) rate and an equivalent major molecular response (MMolR) rate.
在本期《Blood》中，Chalandon 等人报告了一项前瞻性随机研究的结果，该研究比较了标准与较低强度化疗联合伊马替尼治疗新诊断的费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）患者的效果。结果表明，较低强度的治疗可降低早期死亡率而不影响疗效，从而使血液学完全缓解（CR）率显著提高，主要分子缓解（MMolR）率相当。
